Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Toxicol Appl Pharmacol ; 486: 116940, 2024 May.
Article in English | MEDLINE | ID: mdl-38677602

ABSTRACT

L-theanine (L-THE), a non-protein amino acid isolated from Camelia sinensis, has antioxidant properties that could prevent oxidative damage and mitochondrial dysfunction generated by myocardial ischemia and reperfusion (I/R) injury. The present study aimed to identify the effects of pretreatment with L-THE in rat hearts undergoing I/R. Wistar rats received vehicle or 250 mg/Kg L-THE intragastrically for 10 days. On day 11, hearts were removed under anesthesia and exposed to I/R injury in the Langendorff system. Measurement of left ventricular developed pressure and heart rate ex vivo demonstrates that L-THE prevents I/R-induced loss of cardiac function. Consequently, the infarct size of hearts subjected to I/R was significantly decreased when L-THE was administered. L-THE also mitigated I/R-induced oxidative injury in cardiac tissue by decreasing reactive oxygen species and malondialdehyde levels, while increasing the activity of antioxidant enzymes, SOD and CAT. Additionally, L-THE prevents oxidative phosphorylation breakdown and loss of inner mitochondrial membrane potential caused by I/R, restoring oxygen consumption levels, increasing respiratory control and phosphorylation efficiency, as well as buffering calcium overload. Finally, L-THE modifies the expression of genes involved in the antioxidant response through the overexpression of SOD1, SOD2 and CAT; as well as the transcriptional factors PPARα and Nrf2 in hearts undergoing I/R. In conclusion, L-THE confers cardioprotection against I/R injury by preventing oxidative stress, protecting mitochondrial function, and promoting overexpression of antioxidant genes. More studies are needed to place L-THE at the forefront of cardiovascular research and recommend its therapeutic use.


Subject(s)
Antioxidants , Glutamates , Mitochondria, Heart , Myocardial Reperfusion Injury , Oxidative Stress , Rats, Wistar , Animals , Oxidative Stress/drug effects , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/prevention & control , Myocardial Reperfusion Injury/drug therapy , Myocardial Reperfusion Injury/pathology , Antioxidants/pharmacology , Glutamates/pharmacology , Male , Rats , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Reactive Oxygen Species/metabolism , Membrane Potential, Mitochondrial/drug effects , NF-E2-Related Factor 2/metabolism
2.
Toxicol Appl Pharmacol ; 454: 116242, 2022 11 01.
Article in English | MEDLINE | ID: mdl-36108929

ABSTRACT

Nephrotoxicity is an important adverse effect of oxidative stress induced by hexavalent chromium [Cr(VI)]. The effect of ellagic acid, a dietary polyphenolic compound with potent antioxidant activity, was investigated in Cr(VI)-induced kidney injury. Six groups of male Wistar rats were treated intragastrically with vehicle or ellagic acid (15 and 30 mg/kg) for 10 days. On day 10, rats received saline or Cr(VI) (K2Cr2O7 15 mg/kg) subcutaneously. Cr(VI) significantly increased kidney weight, affected kidney function assessed by biomarkers in blood and urine (protein, creatinine and urea nitrogen), caused histological changes (tubular injury and glomerular capillary tuft damage), increased markers of oxidative stress and reduced the activity of antioxidant enzymes. In addition, Cr(VI) altered mitochondrial ultrastructure, impaired mitochondrial respiration, increased lipid peroxidation, and inhibited the function of mitochondrial enzymes. Pretreatment with ellagic acid (30 mg/kg) attenuated all the aforementioned alterations. Furthermore, we explored whether ellagic acid might regulate the tumor necrosis factor-alpha (TNF-α)/receptor-interacting protein kinase 3 (RIPK3) pathway, reducing Cr(VI)-induced tubular necrosis. Cr(VI) upregulated both TNF-α and RIPK3, but ellagic acid only decreased TNF-α levels, having no effect on RIPK3 content. Therefore, understanding the mechanisms through which Cr(VI) promotes necroptosis is crucial for future studies, in order to design strategies to mitigate kidney damage. In conclusion, ellagic acid attenuated Cr(VI)-induced renal alterations by preventing oxidative stress, supporting enzymatic activities, suppressing TNF-α, and preserving mitochondrial ultrastructure and function, most likely due to its antioxidant properties.


Subject(s)
Antioxidants , Tumor Necrosis Factor-alpha , Animals , Antioxidants/metabolism , Antioxidants/pharmacology , Biomarkers/metabolism , Chromium/metabolism , Chromium/toxicity , Creatinine , Ellagic Acid/metabolism , Ellagic Acid/pharmacology , Kidney , Male , Mitochondria/metabolism , Nitrogen/metabolism , Oxidative Stress , Protein Kinases/metabolism , Rats , Rats, Wistar , Tumor Necrosis Factor-alpha/metabolism , Urea/metabolism
3.
Environ Toxicol Pharmacol ; 95: 103960, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35995378

ABSTRACT

Oxidative stress and inflammation are two possible mechanisms related to nephrotoxicity caused by environmental pollutants. Ellagic acid, a powerful antioxidant phytochemical, may have great relevance in mitigating pollutant-induced nephrotoxicity and preventing the progression of kidney disease. This review discusses the latest findings on the protective effects of ellagic acid, its metabolic derivatives, the urolithins, against kidney toxicity caused by heavy metals, pesticides, mycotoxins, and organic air pollutants. We describe the chelating, antioxidant, anti-inflammatory, antifibrotic, antiautophagic, and antiapoptotic properties of ellagic acid to attenuate nephrotoxicity. Furthermore, we present the molecular targets and signaling pathways that are regulated by these antioxidants, and suggest some others that should be explored. Nevertheless, the number of reports is still limited to establish the efficacy of ellagic acid against kidney damage induced by environmental pollutants. Therefore, additional preclinical studies on this topic are required, as well as the development of well-designed clinical trials.


Subject(s)
Air Pollutants , Environmental Pollutants , Kidney Diseases , Mycotoxins , Pesticides , Renal Insufficiency , Air Pollutants/adverse effects , Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Ellagic Acid/metabolism , Ellagic Acid/pharmacology , Ellagic Acid/therapeutic use , Environmental Pollutants/metabolism , Humans , Kidney , Kidney Diseases/chemically induced , Kidney Diseases/metabolism , Kidney Diseases/prevention & control , Oxidative Stress , Pesticides/adverse effects
4.
Life (Basel) ; 11(11)2021 Oct 21.
Article in English | MEDLINE | ID: mdl-34832998

ABSTRACT

Mitochondria are the central target of ischemic preconditioning and postconditioning cardioprotective strategies, which consist of either the application of brief intermittent ischemia/reperfusion (I/R) cycles or the administration of pharmacological agents. Such strategies reduce cardiac I/R injury by activating protective signaling pathways that prevent the exacerbated production of reactive oxygen/nitrogen species, inhibit opening of mitochondrial permeability transition pore and reduce apoptosis, maintaining normal mitochondrial function. Cardioprotection also involves the activation of mitochondrial quality control (MQC) processes, which replace defective mitochondria or eliminate mitochondrial debris, preserving the structure and function of the network of these organelles, and consequently ensuring homeostasis and survival of cardiomyocytes. Such processes include mitochondrial biogenesis, fission, fusion, mitophagy and mitochondrial-controlled cell death. This review updates recent advances in MQC mechanisms that are activated in the protection conferred by different cardiac conditioning interventions. Furthermore, the role of extracellular vesicles in mitochondrial protection and turnover of these organelles will be discussed. It is concluded that modulation of MQC mechanisms and recognition of mitochondrial targets could provide a potential and selective therapeutic approach for I/R-induced mitochondrial dysfunction.

5.
Life Sci ; 277: 119599, 2021 Jul 15.
Article in English | MEDLINE | ID: mdl-33989666

ABSTRACT

The cellular damage caused by redox imbalance is involved in the pathogenesis of many cardiovascular diseases. Besides, redox imbalance is related to the alteration of protein acetylation processes, causing not only chromatin remodeling but also disturbances in so many processes where protein acetylation is involved, such as metabolism and signal transduction. The modulation of acetylases and deacetylases enzymes aids in maintaining the redox homeostasis, avoiding the deleterious cellular effects associated with the dysregulation of protein acetylation. Of note, regulation of protein acetylation has shown protective effects to ameliorate cardiovascular diseases. For instance, HDAC inhibition has been related to inducing cardiac protective effects and it is an interesting approach to the management of cardiovascular diseases. On the other hand, the upregulation of SIRT protein activity has also been implicated in the relief of cardiovascular diseases. This review focuses on the major protein acetylation modulators described, involving pharmacological and bioactive compounds targeting deacetylase and acetylase enzymes contributing to heart protection through redox homeostasis.


Subject(s)
Acetylation/drug effects , Cardiovascular Diseases/enzymology , Heart/physiology , Animals , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/physiopathology , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/metabolism , Histones/metabolism , Homeostasis/drug effects , Humans , Myocardium/metabolism , Oxidation-Reduction , Protective Agents/pharmacology , Protein Processing, Post-Translational/drug effects , Signal Transduction/drug effects , Transcriptional Activation/drug effects
6.
PPAR Res ; 2021: 8895376, 2021.
Article in English | MEDLINE | ID: mdl-33505452

ABSTRACT

Lesions caused by high glucose (HG), hypoxia/reperfusion (H/R), and the coexistence of both conditions in cardiomyocytes are linked to an overproduction of reactive oxygen species (ROS), causing irreversible damage to macromolecules in the cardiomyocyte as well as its ultrastructure. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, promotes beneficial activities counteracting cardiac injury. Therefore, the objective of this work was to determine the potential protective effect of fenofibrate in cardiomyocytes exposed to HG, H/R, and HG+H/R. Cardiomyocyte cultures were divided into four main groups: (1) control (CT), (2) HG (25 mM), (3) H/R, and (4) HG+H/R. Our results indicate that cell viability decreases in cardiomyocytes undergoing HG, H/R, and both conditions, while fenofibrate improves cell viability in every case. Fenofibrate also decreases ROS production as well as nicotinamide adenine dinucleotide phosphate oxidase (NADPH) subunit expression. Regarding the antioxidant defense, superoxide dismutase (SOD Cu2+/Zn2+ and SOD Mn2+), catalase, and the antioxidant capacity were decreased in HG, H/R, and HG+H/R-exposed cardiomyocytes, while fenofibrate increased those parameters. The expression of nuclear factor erythroid 2-related factor 2 (Nrf2) increased significantly in treated cells, while pathologies increased the expression of its inhibitor Keap1. Oxidative stress-induced mitochondrial damage was lower in fenofibrate-exposed cardiomyocytes. Endothelial nitric oxide synthase was also favored in cardiomyocytes treated with fenofibrate. Our results suggest that fenofibrate preserves the antioxidant status and the ultrastructure in cardiomyocytes undergoing HG, H/R, and HG+H/R preventing damage to essential macromolecules involved in the proper functioning of the cardiomyocyte.

7.
Life Sci ; 265: 118763, 2021 Jan 15.
Article in English | MEDLINE | ID: mdl-33189819

ABSTRACT

Obesity is a serious public health problem associated with predisposition to develop metabolic diseases. Over the past decade, several studies in vitro and in vivo have shown that the activity of Krüppel-like factors (KLFs) regulates adipogenesis, adipose tissue function and metabolism. Comprehension of both the origin and development of adipocytes and of adipose tissue could provide new insights into therapeutic strategies to contend against obesity and related metabolic diseases. This review focus on the transcriptional role that KLF family members play during adipocyte differentiation, describes their main interactions and the mechanisms involved in this fine-tuned developmental process. We also summarize new findings of the involvement of several effectors that modulate KLFs expression during adipogenesis, including growth factors, circadian clock proteins, interleukins, nuclear receptors, protein kinases and importantly, microRNAs. Thus, KLFs regulation by these factors and emerging molecules might constitute a potential therapeutic target for anti-obesity intervention.


Subject(s)
Adipogenesis , Kruppel-Like Transcription Factors/physiology , Adipose Tissue/metabolism , Animals , Gene Expression Regulation , Humans , Kruppel-Like Transcription Factors/metabolism
9.
Basic Res Cardiol ; 112(2): 15, 2017 03.
Article in English | MEDLINE | ID: mdl-28160133

ABSTRACT

The demonstration that caveolin-3 overexpression reduces myocardial ischemia/reperfusion injury and our own finding that multiprotein signaling complexes increase in mitochondria in association with caveolin-3 levels, led us to investigate the contribution of caveolae-driven extracellular signal-regulated kinases 1/2 (ERK1/2) on maintaining the function of cardiac mitochondrial subpopulations from reperfused hearts subjected to postconditioning (PostC). Rat hearts were isolated and subjected to ischemia/reperfusion and to PostC. Enhanced cardiac function, reduced infarct size and preserved ultrastructure of cardiomyocytes were associated with increased formation of caveolar structures, augmented levels of caveolin-3 and mitochondrial ERK1/2 activation in PostC hearts in both subsarcolemmal (SSM) and interfibrillar (IFM) subpopulations. Disruption of caveolae with methyl-ß-cyclodextrin abolished cardioprotection in PostC hearts and diminished pho-ERK1/2 gold-labeling in both mitochondrial subpopulations in correlation with suppression of resistance to permeability transition pore opening. Also, differences between the mitochondrial subpopulations in the setting of PostC were evaluated. Caveolae disruption with methyl-ß-cyclodextrin abolished the cardioprotective effect of postconditioning by inhibiting the interaction of ERK1/2 with mitochondria and promoted decline in mitochondrial function. SSM, which are particularly sensitive to reperfusion damage, take advantage of their location in cardiomyocyte boundary and benefit from the cardioprotective signaling driven by caveolae, avoiding injury propagation.


Subject(s)
Caveolae/metabolism , MAP Kinase Signaling System/physiology , Mitochondria, Heart/metabolism , Myocardial Reperfusion Injury/metabolism , Animals , Disease Models, Animal , Immunoblotting , Ischemic Postconditioning , Male , Mitochondrial Membrane Transport Proteins , Mitochondrial Permeability Transition Pore , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Rats , Rats, Wistar
10.
Oxid Med Cell Longev ; 2016: 7367641, 2016.
Article in English | MEDLINE | ID: mdl-27274779

ABSTRACT

The nuclear factor-erythroid 2- (NF-E2-) related factor 2 (Nrf2) is abated and its ability to reduce oxidative stress is impaired in type 2 diabetes and obesity. Thus, the aim of this study was to explore if polymorphisms in Nrf2 and target genes are associated with diabetes and obesity in Mexican mestizo subjects. The rs1800566 of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene, rs7211 of thioredoxin interacting protein (TXNIP) gene, rs2071749 of heme oxygenase-1 (HMOX1) gene, and the rs6721961 and the rs2364723 from Nrf2 gene were genotyped in 627 diabetic subjects and 1020 controls. The results showed that the rs7211 polymorphism is a protective factor against obesity in nondiabetic subjects (CC + CT versus TT, OR = 0.40, P = 0.005) and in women (CC versus CT + TT, OR = 0.7, P = 0.016). TT carriers had lower high-density lipoprotein cholesterol levels and lower body mass index. The rs2071749 was positively associated with obesity (AA versus AG + GG, OR = 1.25, P = 0.026). Finally, the rs6721961 was negatively associated with diabetes in men (CC versus CA + AA, OR = 0.62, P = 0.003). AA carriers showed lower glucose concentrations. No association was found for rs1800566 and rs2364723 polymorphisms. In conclusion, the presence of Nrf2 and related genes polymorphisms are associated with diabetes and obesity in Mexican patients.


Subject(s)
Carrier Proteins/genetics , Diabetes Mellitus/genetics , Heme Oxygenase-1/genetics , NF-E2-Related Factor 2/genetics , Obesity/genetics , Polymorphism, Single Nucleotide , Adult , Biomarkers/blood , Blood Glucose/analysis , Body Mass Index , Case-Control Studies , Chi-Square Distribution , Diabetes Mellitus/diagnosis , Diabetes Mellitus/enzymology , Diabetes Mellitus/ethnology , Female , Gene Frequency , Genetic Association Studies , Genetic Predisposition to Disease , Glycated Hemoglobin/analysis , Humans , Lipids/blood , Logistic Models , Male , Mexico , Middle Aged , Multivariate Analysis , NAD(P)H Dehydrogenase (Quinone)/genetics , Obesity/diagnosis , Obesity/enzymology , Obesity/ethnology , Odds Ratio , Oxidative Stress/genetics , Phenotype , Protective Factors , Risk Factors , Sex Factors
11.
J Ren Nutr ; 26(4): 237-44, 2016 07.
Article in English | MEDLINE | ID: mdl-26915483

ABSTRACT

OBJECTIVE: Chronic kidney disease (CKD) is a worldwide public health problem, and proteinuria may accelerate the progression of CKD, being oxidative stress a common mechanism in nondiabetic or diabetic proteinuric kidney disease. This study was designed to evaluate the effect of the dietary supplementation with curcumin (CUR) on the redox status and the nuclear factor erythroid 2-related factor 2 (Nrf2) activation in patients with nondiabetic or diabetic proteinuric CKD. DESIGN: Randomized double-blind placebo-controlled clinical trial. SUBJECTS: A total of 101 Mexican patients from the National Institute of Cardiology "Ignacio Chavez", with nondiabetic or diabetic proteinuric CKD (proteinuria ≥ 1 g protein/24 hours), aged 20 to 70 years; 60% were male, and 51% were diabetic. INTERVENTION: Patients with nondiabetic proteinuric CKD received placebo (n = 26) or CUR 320 mg/day (n = 24) for 8 weeks, and patients with diabetic proteinuric CKD were intervened with placebo (n = 23) or CUR 320 mg/day (n = 28) for the same period. MAIN OUTCOME MEASURE: Anthropometrical, clinical, and biochemical characteristics, as well as oxidative stress markers, antioxidant enzyme activities and Nrf2 activation were evaluated at baseline and after intervention. RESULTS: The intervention with CUR did not improve proteinuria, estimated glomerular filtration rate, or lipid profile. However, in plasma, CUR attenuated lipid peroxidation in individuals with nondiabetic proteinuric CKD (P<.05) and enhanced the antioxidant capacity in subjects with diabetic proteinuric CKD (P<.05). No effect of CUR was observed on the antioxidant enzymes activities or Nrf2 activation. CONCLUSIONS: Dietary supplementation with CUR has the potential to reduce oxidative stress in Mexican patients with nondiabetic or diabetic proteinuric CKD. Studies with higher doses of CUR and longer follow-up are granted to confirm our findings.


Subject(s)
Curcumin/administration & dosage , Diabetic Nephropathies/drug therapy , NF-E2-Related Factor 2/metabolism , Oxidation-Reduction/drug effects , Proteinuria/drug therapy , Renal Insufficiency, Chronic/drug therapy , Adult , Aged , Body Mass Index , Curcuma/chemistry , Dietary Supplements , Double-Blind Method , Female , Glomerular Filtration Rate , Humans , Male , Mexico , Middle Aged , NF-E2-Related Factor 2/genetics , Oxidative Stress/drug effects , Young Adult
12.
Eur J Pharmacol ; 765: 472-81, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26387613

ABSTRACT

Reperfusion damage involves opening of the mitochondrial permeability transition pore (mPTP) and loss of ATP synthesis. Several cardioprotective pathways are activated by ischemic or pharmacological post-conditioning (PC). The mechanisms that are activated by PC in no co-morbidity murine models include: activation of rescue kinases, oxidative stress reduction, glycolytic flux regulation and preservation of ATP synthesis. However, relatively scarce efforts have been made to define whether the efficacy of PC signaling is blunted by risk factors or systemic diseases associated with ischemic heart pathology. Experimental evidence has shown that the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling is a main mechanism activated by PC in hearts without pathological history. In this work we evaluated the participation of the NO pathway, through downstream kinase activation and inhibition of mPTP in hearts with previous infarct. Myocardial infarction was induced with a single dose of isoproterenol (85 mg/kg i.p.) to male Wistar rats. After 24 h, the hearts were mounted into the Langendorff system and subjected to 30 min of ischemia and 60 min of reperfusion. PC consisted of 5 cycles of 30 s of reperfusion/30 s of ischemia, then the hearts were reperfused with or without inhibitors of the NO/cGMP pathway. PC activates the NO/cGMP pathway, as increased cGMP and NO levels were detected in isoproterenol-treated hearts. The cardioprotective effect of PC was abolished with both L-NAME (inhibitor of constitutive NO synthase) and ODQ (inhibitor of soluble guanylate cyclase), whereas the NO donor (DETA-NO) restored cardioprotection even in the presence of L-NAME or ODQ. We also found that mitochondrial structure and function was preserved in PC hearts. We conclude that PC exerts cardioprotection in hearts with previous infarct by maintaining mitochondrial structure and function through NO-dependent pathway.


Subject(s)
Guanosine Monophosphate/metabolism , Ischemic Postconditioning/methods , Myocardial Infarction/metabolism , Myocardial Infarction/prevention & control , Nitric Oxide/metabolism , Animals , Guanosine Monophosphate/antagonists & inhibitors , Male , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Mitochondria, Heart/ultrastructure , Myocardial Infarction/pathology , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/pathology , Myocardial Reperfusion Injury/prevention & control , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/antagonists & inhibitors , Rats , Rats, Wistar , Signal Transduction/drug effects , Signal Transduction/physiology
13.
Article in English | MEDLINE | ID: mdl-26345660

ABSTRACT

It has been shown that curcumin (CUR), a polyphenol derived from Curcuma longa, exerts a protective effect against gentamicin- (GM-) induced nephrotoxicity in rats, associated with a preservation of the antioxidant status. Although mitochondrial dysfunction is a hallmark in the GM-induced renal injury, the role of CUR in mitochondrial protection has not been studied. In this work, LLC-PK1 cells were preincubated 24 h with CUR and then coincubated 48 h with CUR and 8 mM GM. Treatment with CUR attenuated GM-induced drop in cell viability and led to an increase in nuclear factor (erythroid-2)-related factor 2 (Nrf2) nuclear accumulation and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) cell expression attenuating GM-induced losses in these proteins. In vivo, Wistar rats were injected subcutaneously with GM (75 mg/Kg/12 h) during 7 days to develop kidney mitochondrial alterations. CUR (400 mg/Kg/day) was administered orally 5 days before and during the GM exposure. The GM-induced mitochondrial alterations in ultrastructure and bioenergetics as well as decrease in activities of respiratory complexes I and IV and induction of calcium-dependent permeability transition were mostly attenuated by CUR. Protection of CUR against GM-induced nephrotoxicity could be in part mediated by maintenance of mitochondrial functions and biogenesis with some participation of the nuclear factor Nrf2.

14.
Pharmacol Res ; 97: 84-103, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25941011

ABSTRACT

Traditional drugs or therapies rarely have effects on regression of chronic liver diseases, which result in many cases from sustained oxidative stress. In recent years, ellagic acid (EA) has gained attention due to its multiple biological activities and several molecular targets. This is the first review focused on the pharmacological properties and on the molecular mechanisms activated by EA in terms of liver protection. EA possesses antioxidant, antihepatotoxic, antisteatosic, anticholestatic, antifibrogenic, antihepatocarcinogenic and antiviral properties that improves the hepatic architectural and functions against toxic and pathological conditions. The molecular mechanisms that EA activates include the scavenging of free radicals, regulation of phase I and II enzymes, modulation of proinflammatory and profibrotic cytokines synthesis, the regulation of biochemical pathways involved in the synthesis and degradation of lipids as well as the maintenance of essential trace elements levels. EA also inhibits hepatic stellate cells and mast cells activation, the proliferation of transformed cells, as well as viral replication by increasing antioxidant response, induction of apoptosis, downregulation of genes involved in cell cycle and angiogenesis, and stimulation of cellular immune response. Despite the enormous therapeutic potential of EA as an innovative pharmacological strategy, the number of phase I and II trials in patients is scarce, precluding its clinical application. In these sense, the use of new delivery systems that enhances EA bioavailability would improve the results already obtained. Also it remains to be determined if treatment with urolithins instead of EA would represent a better strategy in hepatic disease treatment.


Subject(s)
Chemical and Drug Induced Liver Injury/prevention & control , Ellagic Acid/pharmacology , Protective Agents/pharmacology , Animals , Antiviral Agents/pharmacology , Cholestasis/prevention & control , Ellagic Acid/chemistry , Ellagic Acid/pharmacokinetics , Fatty Liver/prevention & control , Hepatic Stellate Cells/drug effects , Hepatitis Viruses/drug effects , Humans , Liver Neoplasms/prevention & control
15.
Biol Trace Elem Res ; 167(1): 130-45, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25774041

ABSTRACT

Hexavalent chromium [Cr(VI)] compounds are extremely toxic and carcinogenic. Despite the vast quantity of reports about Cr(VI) toxicity, the information regarding its effects when it is intraperitoneally (i.p.) administered is still limited. In contrast, it has been shown that curcumin prevents hepatotoxicity induced by a single intraperitoneal injection of 15 mg/kg body weight (b.w.) of potassium dichromate (K2Cr2O7). This study aims to evaluate oxidative stress markers, the activity of antioxidant enzymes, and the potential histological injury in brain, heart, lung, kidney, spleen, pancreas, stomach, and intestine from rats treated with a hepatotoxic dose of K2Cr2O7 (15 mg/kg b.w.), and the effect of curcumin pretreatment. Rats were divided into four groups: control, curcumin, K2Cr2O7, and curcumin+K2Cr2O7. At the end of the treatment, plasma and ascites fluid were collected and target organs were dissected out for biochemical and histological analysis. K2Cr2O7 induced hepatotoxicity but failed to induce in all the other studied organs either oxidative or histological injury, since levels of malondialdehyde (MDA), glutathione (GSH), and the activity of superoxide dismutase (SOD), catalase (CAT), and related GSH enzymes were unchanged. As expected, curcumin was safe. Lack of K2Cr2O7-induced toxicity in those target organs could be due to the following: (1) route of administration, (2) absorption through the portal circulation, (3) lower dose than needed, (4) short time of exposure, or (5) repeated doses are required to produce damage. Thus, the intraperitoneal injection of 15 mg/kg of K2Cr2O7, that is able to induce hepatotoxicity, was unable to induce histological and oxidative damage in other target organs.


Subject(s)
Biomarkers/metabolism , Curcumin/pharmacology , Oxidative Stress/drug effects , Potassium Dichromate/toxicity , Analysis of Variance , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Biomarkers/blood , Body Weight/drug effects , Brain/drug effects , Brain/metabolism , Brain/pathology , Catalase/metabolism , Dose-Response Relationship, Drug , Gastric Mucosa/metabolism , Injections, Intraperitoneal , Intestinal Mucosa/metabolism , Intestines/drug effects , Intestines/pathology , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Liver/drug effects , Liver/metabolism , Liver/pathology , Lung/drug effects , Lung/metabolism , Lung/pathology , Male , Malondialdehyde/blood , Malondialdehyde/metabolism , Myocardium/metabolism , Myocardium/pathology , Organ Size/drug effects , Pancreas/drug effects , Pancreas/metabolism , Pancreas/pathology , Potassium Dichromate/administration & dosage , Rats, Wistar , Spleen/drug effects , Spleen/metabolism , Spleen/pathology , Stomach/drug effects , Stomach/pathology , Superoxide Dismutase/metabolism
16.
J Biochem Mol Toxicol ; 28(11): 522-7, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25130536

ABSTRACT

Occupational and environmental exposure to potassium dichromate (K2Cr2O7), a hexavalent chromium compound, can result in liver damage associated with oxidative stress and mitochondrial dysfunction. The purpose of this study was to evaluate the effect of the antioxidant curcumin (400 mg/kg b.w.) on the K2Cr2O7-induced injury, with special emphasis on ascitic fluid accumulation and oxidative phosphorylation mitochondrial enzymes and the adenosine triphosphate (ATP) levels in isolated mitochondria from livers of rats treated with K2Cr2O7 (15 mg/kg b.w.). Thus, curcumin attenuated the ascites generation, prevented the decrease in the activities of aconitase and F1F0 ATPase, and maintained the ATP levels. The activity of complex II was not completely reestablished by curcumin, whereas complexes III and IV activities were unchanged.


Subject(s)
Ascites/prevention & control , Curcumin/therapeutic use , Mitochondria, Liver/drug effects , Potassium Dichromate/toxicity , Aconitate Hydratase/metabolism , Adenosine Triphosphate/metabolism , Animals , Ascites/chemically induced , Ascites/metabolism , Ascitic Fluid/physiology , Kidney/drug effects , Liver/drug effects , Male , Mitochondria, Liver/enzymology , Mitochondria, Liver/metabolism , Oxidative Stress/physiology , Proton-Translocating ATPases/metabolism , Rats , Rats, Wistar
17.
J Pharm Pharmacol ; 66(9): 1271-81, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24779924

ABSTRACT

OBJECTIVES: Cisplatin (CP) is an antineoplastic agent that induces nephrotoxicity and oxidative stress. S-allylcysteine (SAC) is a garlic-derived antioxidant. This study aims to explore whether SAC protects against CP-induced nephrotoxicity in rats. METHODS: In the first stage, the SAC protective dose was determined by measuring renal damage and the oxidative stress markers malondialdehyde, oxidized proteins and glutathione in rats injected with CP. In the second stage, the effect of a single dose of SAC on the expression of nuclear factor-erythroid 2-related factor-2 (Nrf2), protein kinase C beta 2 (PKCß2) and nicotinamide adenine dinucleotide phosphate oxidase subunits (p47(phox) and gp91(phox) ) was studied. In addition, the effect of SAC on oxidative stress markers and on the activity of catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GR) in isolated proximal and distal tubules were evaluated. KEY FINDINGS: SAC (25 mg/kg) prevented the CP-induced renal damage and attenuated CP-induced decrease in Nrf2 levels and increase in PKCß2, p47(phox) and gp91(phox) expression in renal cortex and oxidative stress and decrease in the activity of CAT, GPx and GR in proximal and distal tubules. CONCLUSIONS: These data suggest that SAC provides renoprotection by attenuating CP-induced oxidative stress and decrease in the activity of CAT, GPx and GR.


Subject(s)
Antioxidants/therapeutic use , Cisplatin/adverse effects , Cysteine/analogs & derivatives , Garlic/chemistry , Kidney Diseases/prevention & control , Kidney/drug effects , Oxidative Stress/drug effects , Animals , Antineoplastic Agents/adverse effects , Antioxidants/metabolism , Antioxidants/pharmacology , Catalase/metabolism , Cisplatin/therapeutic use , Cysteine/pharmacology , Cysteine/therapeutic use , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Kidney/metabolism , Kidney Diseases/metabolism , Male , Malondialdehyde/metabolism , Membrane Glycoproteins/metabolism , NADPH Oxidase 2 , NADPH Oxidases/metabolism , NF-E2-Related Factor 2/metabolism , Phytotherapy , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Protein Kinase C beta/metabolism , Rats, Wistar , Reactive Oxygen Species/metabolism
18.
Food Chem Toxicol ; 69: 182-201, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24751969

ABSTRACT

Occupational or environmental exposures to heavy metals produce several adverse health effects. The common mechanism determining their toxicity and carcinogenicity is the generation of oxidative stress that leads to hepatic damage. In addition, oxidative stress induced by metal exposure leads to the activation of the nuclear factor (erythroid-derived 2)-like 2/Kelch-like ECH-associated protein 1/antioxidant response elements (Nrf2/Keap1/ARE) pathway. Since antioxidant and chelating agents are generally used for the treatment of heavy metals poisoning, this review is focused on the protective role of curcumin against liver injury induced by heavy metals. Curcumin has shown, in clinical and preclinical studies, numerous biological activities including therapeutic efficacy against various human diseases and anti-hepatotoxic effects against environmental or occupational toxins. Curcumin reduces the hepatotoxicity induced by arsenic, cadmium, chromium, copper, lead and mercury, prevents histological injury, lipid peroxidation and glutathione (GSH) depletion, maintains the liver antioxidant enzyme status and protects against mitochondrial dysfunction. The preventive effect of curcumin on the noxious effects induced by heavy metals has been attributed to its scavenging and chelating properties, and/or to the ability to induce the Nrf2/Keap1/ARE pathway. However, additional research is needed in order to propose curcumin as a potential protective agent against liver damage induced by heavy metals.


Subject(s)
Curcumin/pharmacology , Liver/drug effects , Metals, Heavy/toxicity , Protective Agents/pharmacology , Animals , Arsenic/toxicity , Cadmium/toxicity , Copper/toxicity , Humans , Intracellular Signaling Peptides and Proteins/metabolism , Kelch-Like ECH-Associated Protein 1 , Lead/toxicity , Liver/metabolism , Liver/pathology , Mercury/toxicity , NF-E2-Related Factor 2/metabolism , Oxidative Stress/drug effects
19.
Article in English | MEDLINE | ID: mdl-23956771

ABSTRACT

Curcumin is a polyphenol derived from turmeric with recognized antioxidant properties. Hexavalent chromium is an environmental toxic and carcinogen compound that induces oxidative stress. The objective of this study was to evaluate the potential protective effect of curcumin on the hepatic damage generated by potassium dichromate (K2Cr2O7) in rats. Animals were pretreated daily by 9-10 days with curcumin (400 mg/kg b.w.) before the injection of a single intraperitoneal of K2Cr2O7 (15 mg/kg b.w.). Groups of animals were sacrificed 24 and 48 h later. K2Cr2O7-induced damage to the liver was evident by histological alterations and increase in the liver weight and in the activity of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and alkaline phosphatase in plasma. In addition, K2Cr2O7 induced oxidative damage in liver and isolated mitochondria, which was evident by the increase in the content of malondialdehyde and protein carbonyl and decrease in the glutathione content and in the activity of several antioxidant enzymes. Moreover, K2Cr2O7 induced decrease in mitochondrial oxygen consumption, in the activity of respiratory complex I, and permeability transition pore opening. All the above-mentioned alterations were prevented by curcumin pretreatment. The beneficial effects of curcumin against K2Cr2O7-induced liver oxidative damage were associated with prevention of mitochondrial dysfunction.

20.
Oxid Med Cell Longev ; 2012: 269039, 2012.
Article in English | MEDLINE | ID: mdl-22919438

ABSTRACT

Renal injury resulting from renal ablation induced by 5/6 nephrectomy (5/6NX) is associated with oxidant stress, glomerular hypertension, hyperfiltration, and impaired Nrf2-Keap1 pathway. The purpose of this work was to know if the bifunctional antioxidant curcumin may induce nuclear translocation of Nrf2 and prevents 5/6NX-induced oxidant stress, renal injury, decrease in antioxidant enzymes, and glomerular hypertension and hyperfiltration. Four groups of rats were studied: (1) control, (2) 5/6NX, (3) 5/6NX +CUR, and (4) CUR (n = 8-10). Curcumin was given by gavage to NX5/6 +CUR and CUR groups (60 mg/kg/day) starting seven days before surgery. Rats were studied 30 days after NX5/6 or sham surgery. Curcumin attenuated 5/6NX-induced proteinuria, systemic and glomerular hypertension, hyperfiltration, glomerular sclerosis, interstitial fibrosis, interstitial inflammation, and increase in plasma creatinine and blood urea nitrogen. This protective effect was associated with enhanced nuclear translocation of Nrf2 and with prevention of 5/6NX-induced oxidant stress and decrease in the activity of antioxidant enzymes. It is concluded that the protective effect of curcumin against 5/6NX-induced glomerular and systemic hypertension, hyperfiltration, renal dysfunction, and renal injury was associated with the nuclear translocation of Nrf2 and the prevention of both oxidant stress and the decrease of antioxidant enzymes.


Subject(s)
Cell Nucleus/metabolism , Curcumin/pharmacology , Glomerular Filtration Rate/drug effects , Hypertension/prevention & control , Kidney Glomerulus/enzymology , NF-E2-Related Factor 2/metabolism , Oxidative Stress/drug effects , Animals , Antioxidants/metabolism , Blood Urea Nitrogen , Cell Nucleus/drug effects , Creatinine/blood , Hypertension/blood , Hypertension/complications , Hypertension/physiopathology , Kidney Glomerulus/physiopathology , Lipid Peroxidation/drug effects , Male , Mitochondria/drug effects , Mitochondria/metabolism , Nephrectomy , Oxidants/toxicity , Oxygen Consumption/drug effects , Protein Transport/drug effects , Proteinuria/blood , Proteinuria/complications , Proteinuria/physiopathology , Punctures , Rats , Rats, Wistar , Systole/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...